Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016050 · ClinicalTrials.gov registry record · NA
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
A NA study, sponsored by Happify.
- Completed
- Registry status
- NA
- Development phase
- 367
- Enrollment target
NCT05016050: Completed NA study, sponsored by Happify.
NCT05016050 is a NA study that has completed, run by Happify. The registered enrollment target is 367 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05016050, a NA study, has completed, sponsored by Happify.
- COMPLETED
- Registry status
- NA
- Development phase
- 367 participants
- Enrollment target
Study Summary
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.
Primary Outcome
A 9-item self-report measure to assess symptoms of depression
Interventions
- DEVICE HPDT-DA-013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2023-04-14 |
| Phase | NA |
What the finished NCT05016050 record still lists
NCT05016050 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which HPDT-DA-013 is the first listed.
NCT05016050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05016050 about?
NCT05016050 is a clinical study titled "Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)". Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.
What is the current status of trial NCT05016050?
This trial is currently completed. It is a NA study. The enrollment target is 367 participants. The study started on 2021-08-09. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05016050?
The interventions under investigation include: HPDT-DA-013 (DEVICE).
Who is sponsoring clinical trial NCT05016050?
This trial is sponsored by Happify, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05016050's enrollment target sits among peer trials
367 284th of 2000 higher than 1,717 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI